Louis Moore Bacon's TDAC Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 100,000 shares of Translational Development Acquisition Corp. (TDAC) worth $1.06 M, representing 0.02% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 4 quarters.
Based on 13F filings, Louis Moore Bacon has maintained this position in TDAC for several quarters, showing initial confidence in the investment.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Translational Development Acquisition (TDAC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Translational Development Acquisition (TDAC) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2025 | +100,000 | New Buy | 100,000 | $10.30 |
Louis Moore Bacon's Translational Development Acquisition Investment FAQs
Louis Moore Bacon first purchased Translational Development Acquisition Corp. (TDAC) in Q2 2025, acquiring 100,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Translational Development Acquisition Corp. (TDAC) for 4 quarters since Q2 2025.
Louis Moore Bacon's largest addition to Translational Development Acquisition Corp. (TDAC) was in Q2 2025, adding 100,000 shares worth $1.03 M.
According to the latest 13F filing for Q1 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 100,000 shares of Translational Development Acquisition Corp. (TDAC), valued at approximately $1.06 M.
As of the Q1 2026 filing, Translational Development Acquisition Corp. (TDAC) represents approximately 0.02% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Translational Development Acquisition Corp. (TDAC) was 100,000 shares, as reported at the end of Q2 2025.